Biotech

SKYRIZI® is an interleukin-23 inhibitor used for the treatment of moderate to severe plaque psoriasis. 1 In clinical studies, SKYRIZI® significantly improved levels of skin clearance after just 16 weeks and maintained clearance at one year . 1 New Brunswick lists SKYRIZI® on its provincial formulary effective March 19, 2020 . Yukon lists SKYRIZI® on its formulary effective April 1, 2020 . British Columbia lists ...
  • SKYRIZI® is an interleukin-23 (IL-23) inhibitor used for the treatment of moderate to severe plaque psoriasis. 1
  • In clinical studies, SKYRIZI® significantly improved levels of skin clearance after just 16 weeks and maintained clearance at one year (52 weeks). 1
  • New Brunswick lists SKYRIZI® on its provincial formulary effective March 19, 2020 .
  • Yukon lists SKYRIZI® on its formulary effective April 1, 2020 .
  • British Columbia lists SKYRIZI ® on its provincial formulary effective May 05, 2020 .
  • Newfoundland and Labrador lists SKYRIZI ® on its provincial formulary effective September 16, 2020 .

 ABBVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company, announced today that SKYRIZI® (risankizumab) is now listed as a special authorization drug or exception drug status on the formularies of New Brunswick Yukon British Columbia and Newfoundland and Labrador for the treatment of moderate to severe plaque psoriasis.

SKYRIZI® is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally, and is the only IL-23 inhibitor to arrive at a positive conclusion with the pCPA.

"I have been fortunate to be involved in the clinical trials. SKYRIZI® has improved the quality of life of my patients with psoriasis by offering them clear skin," states Dr. Irina Turchin , MD, FRCPC, Fredericton , NB.  "It is great to see that this treatment is now available to more patients in New Brunswick ."

Psoriasis is a chronic condition affecting 125 million people worldwide, including 1 million Canadians, and many patients despite treatment still do not reach their goals or lose treatment response over time. 2-4 The most common form is plaque psoriasis, which affects approximately 90% of patients. 5

"I am excited to be able to offer SKYRIZI® to patients with moderate to severe psoriasis in British Columbia as it is now listed on the provincial Pharmacare formulary.  Having experience with the medication in clinical trials, I have personally seen how it provides durable and complete skin clearance for many patients. Patients are particularly happy with the dosing schedule," explains Dr Chih-ho Hong, MD, FRCPC, Dermatologist.

Psoriasis has a genetic basis and about one-third of people with psoriasis have at least one family member with the disease. 5 Of note, the prevalence of psoriasis is 5- to 10-fold higher in Newfoundland and Labrador than in the rest of Canada . 6

"PsoriasisNL is pleased to learn of this listing of another treatment for psoriasis for the patients of our province. We would like to thank the Government of Newfoundland and Labrador for their continued support of advanced therapeutics for the patients of this province who suffer from severe psoriasis. As the province with the highest prevalence of this disease, the availability of these treatments have greatly increased the quality of life for those who suffer from psoriasis", explains Deva Murthy, President, PsoriasisNL.

Information regarding specific reimbursement criteria may be found by consulting the links below:

About SKYRIZI ®
SKYRIZI® is a novel, humanized immunoglobulin monoclonal antibody designed to selectively inhibit IL-23, a naturally occurring cytokine involved in inflammatory and immune responses. 1 On April 17, 2019 , SKYRIZI™ received a NOC from Health Canada for the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy, based on results from clinical studies showing significant improvement in levels of skin clearance after just 16 weeks and at 52 weeks with every 3-month dosing in more than 2000 adult patients. 1 Four pivotal Phase 3 studies, ultIMMa-1, ultIMMa-2, IMMvent and IMMhance evaluated more than 2,000 patients with moderate to severe plaque psoriasis. 4 Canadians living with moderate to severe plaque psoriasis were well represented in all four of the pivotal clinical trials leading to Health Canada's approval, showing the Canadian leadership in this clinical development program.

About AbbVie in Dermatology
For more than a decade, AbbVie has worked to uncover new solutions and improve care for people with serious skin diseases. With a broad clinical trial program, we continue to actively research and adapt to the evolving needs of the dermatology community and advance our pipeline to help people achieve their treatment goals and live beyond their skin disease.

About AbbVie Care
The AbbVie Care program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, lab work reminders and coordination, personalized education and ongoing disease management support throughout the treatment journey.  For more information, consult abbviecare.ca

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com . Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

References:

1.

SKYRIZI ® (risankizumab) [Canadian Product Monograph].  AbbVie Corporation, April 17, 2019.

2.

International Federation of Psoriasis Associations. Accessed March 22, 2019. Available at: https://ifpa-pso.com/wp-content/uploads/2017/01/Brochure-Psoriasis-is-a-serious-disease-deserving-global-attention.pdf .

3.

Mroweitz, U., et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011 Jan; 303(1): 1–10.

4.

Levin, et al. Biologic fatigue in psoriasis. J Dermatolog Treat. 2014 Feb;25(1):78-82. doi: 10.3109/09546634.2013.826341.

5.

Canadian Dermatology Association – Psoriasis . Accessed on September 30, 2020.

6.

Nall, L., Gulliver, W., Charmley, P. and Farber, E.M. (1999) Search for the psoriasis susceptibility gene: The Newfoundland Study. Cutis, 64, 323–329.)

SOURCE AbbVie Canada

News Provided by Canada Newswire via QuoteMedia

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Results suggest broader applications for DehydraTECH-CBD beyond hypertension

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to issue follow-up results from human clinical study HYPER-H21-2 confirming that DehydraTECHTM-processed cannabidiol ("CBD") reduces arterial stiffness, potentially broadening its application to treatment of cardiovascular and other disease states beyond hypertension where it has already shown tremendous promise

Keep reading... Show less
Lexaria's DehydraTECH-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Lexaria's DehydraTECH-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

(TheNewswire)

Lexaria Bioscience Corp.

Results suggest broader applications for DehydraTECH-CBD beyond hypertension

Keep reading... Show less
BioHarvest Sciences Inc. Produces Significant Amount of Cannabis Without Growing the Cannabis Plant

BioHarvest Sciences Inc. Produces Significant Amount of Cannabis Without Growing the Cannabis Plant

  • Cannabis produced has a Trichomes density of up to 200 times greater than in a plant-grown product while solving major industry challenges of consistency, safety, and environmental sustainability
  • The Company is ready to engage with key players in the global Cannabis industry

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") has announced that it has produced a meaningful amount (10 kilograms) of full-spectrum Cannabis biomass at a commercial scale without growing the plant itself. (For full illustration, watch the "Cannabis Without Plants - History in the Making" video at https:youtu.beNAurl6oa1xo)

Keep reading... Show less
Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference

Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference

Lexaria Bioscience Corp. (NASDAQ: LEXX) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global small cap space.

Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/december-2021-global/.

Keep reading... Show less

Amgen Announces New Data Being Presented At ASH 2021

- Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63 rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia and virtually, from Dec. 11-14, 2021 .

"The data being presented at ASH demonstrates Amgen's commitment to reaching more patients with our innovative hematology medicines and improving the patient experience by exploring more convenient administrations for people living with blood cancers," said David M. Reese , M.D., executive vice president of Research and Development at Amgen. "By accelerating the development and delivery of transformative medicines in difficult to treat and vulnerable patient populations, including children and pregnant women, we continue to focus on the relentless pursuit of breakthroughs for blood cancer patients and their families."

Keep reading... Show less

Upadacitinib Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease

ABBVie (NYSE: ABBV) today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission a,b and endoscopic response c at week 12. 1 The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60 percent having previously failed two or more biologics. 1 U-EXCEED is the first of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease. 1

"The data from this first Phase 3 induction study in Crohn's disease suggest upadacitinib may help address the needs of patients suffering from this disease, as demonstrated in stringent endpoints such as endoscopic response," said Michael Severino , M.D., vice chairman and president, AbbVie. "We continue to leverage our expertise in IBD by driving research and development that help shape the IBD landscape and elevate standards of care for patients."

Keep reading... Show less

Top News

Related News